ConductScience.org, home

Paper42903092PubMed

Vitiligo onset following anti-inflammatory biological therapy: a scoping review.

Romagnuolo M and 5 others. Front Immunol, 2026.

Cite this record

ConductScience Library. Vitiligo onset following anti-inflammatory biological therapy: a scoping review. Papers, record 42903092. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42903092

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vitiligo onset following anti-inflammatory biological therapy: a scoping review.
Journal
Front Immunol
Year
2026
Publication types
Journal Article, Scoping Review, Systematic Review
Revised in PubMed
2026-11-02

Source PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Romagnuolo MMaurizio
2Moltrasio CChiara
3Rossi LCLuisa Carlotta
4Tavoletti GGianluca
5Marzano AVAngelo Valerio
6Alberti Violetti SSilvia

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
VitiligoMajor topic
Anti-Inflammatory AgentsMajor topic
Biological TherapyMajor topic
Humans
Adult
Male
Female
Antibodies, Monoclonal
Tumor Necrosis Factor-alpha
Cytokines
Middle Aged

Source PubMed

Download CSV of topics

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123284977Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo.PLoS One2012https://conductscience.org/library/papers/23284977PubMed
226149498Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.Br J Dermatol2015https://conductscience.org/library/papers/26149498PubMed
338646109Vitiligo in a Patient Receiving Adalimumab for Idiopathic Uveitis.Turk J Ophthalmol2024https://conductscience.org/library/papers/38646109PubMed
435781265Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor palbociclib.Int J Dermatol2023https://conductscience.org/library/papers/35781265PubMed
541578766Co-Occurrence of Inflammatory Bowel Disease in Patients with Vitiligo: A Systematic Review and Meta-Analysis.Turk J Gastroenterol2026https://conductscience.org/library/papers/41578766PubMed
639925013Cutaneous Side Effects of PD-1 Inhibitors: A Single-Center Retrospective Study.Int J Dermatol2025https://conductscience.org/library/papers/39925013PubMed
728782213New onset vitiligo following commencement of infliximab in Crohn disease.Intern Med J2017https://conductscience.org/library/papers/28782213PubMed
829175284Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study.J Invest Dermatol2018https://conductscience.org/library/papers/29175284PubMed
941345471Vitiligo.Nat Rev Dis Primers2025https://conductscience.org/library/papers/41345471PubMed
1027291924New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases.J Eur Acad Dermatol Venereol2017https://conductscience.org/library/papers/27291924PubMed
1131872933Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis.J Cosmet Dermatol2020https://conductscience.org/library/papers/31872933PubMed
1239742272Biologic drugs induced vitiligo: case reports and review of literature.Front Immunol2024https://conductscience.org/library/papers/39742272PubMed
1334699032Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.Am J Clin Dermatol2022https://conductscience.org/library/papers/34699032PubMed
1423740223Association between vitiligo and atopic disorders: a pilot study.JAMA Dermatol2013https://conductscience.org/library/papers/23740223PubMed
1536741377Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature.Front Immunol2022https://conductscience.org/library/papers/36741377PubMed
1637586898Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice.Ann Dermatol Venereol2023https://conductscience.org/library/papers/37586898PubMed
1736181252Generalized vitiligo in a psoriatic patient treated with ixekizumab.Dermatol Ther2022https://conductscience.org/library/papers/36181252PubMed
1834616133A Case of New-Onset Vitiligo in a Healthy Volunteer After Administration of Adalimumab.Ann Dermatol2021https://conductscience.org/library/papers/34616133PubMed
1930317450Association Between Psoriasis and Vitiligo: A Systematic Review and Meta-Analysis.Am J Clin Dermatol2019https://conductscience.org/library/papers/30317450PubMed
2029200787A Type II Segmental Vitiligo Developed under Infliximab Treatment for Ulcerative Colitis.Ann Dermatol2017https://conductscience.org/library/papers/29200787PubMed

See all 44 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first.

PMIDTitleJournalYearIn Papers
42961470[Latest developments in human papillomavirus in head and neck oncology-highlights from the 2026 ASCO Annual Meeting].HNO2026https://conductscience.org/library/papers/42961470

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42903092

GET https://conductscience.org/api/papers/v1/42903092/references?page=2